Clinical Research Directory
Browse clinical research sites, groups, and studies.
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
Sponsor: First Hospital of China Medical University
Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
Official title: In Which Tumor Burden Range Does Advanced Hepatocellular Carcinoma Patients Benefit More from Hepatic Arterial Infusion Chemotherapy Plus Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors Than Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors? a Multi-center, Retrospective, Propensity Score Matching Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
97
Start Date
2024-08-16
Completion Date
2025-05-30
Last Updated
2024-10-08
Healthy Volunteers
No
Conditions
Interventions
hepatic artery infusion chemotherapy
Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
Tyrosine kinase inhibitor (TKIs)
TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
Immune Checkpoint Inhibitors
ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
Locations (1)
The first hospital of China medical university
Shenyang, Liaoning, China